L-R: Biosynth COO Thomas Eisele; Matt Gunnison; Gu Hong Jian, Committee Member of the Wuzhong Economic Development Zone Party Work Committee and Deputy Director of the Management Committee; Alessandra Vismara, Biosynth General Manager; Gu Xiao Dong, Deputy Secretary of the Wuzhong District Committee and District Mayor; Sacha Bachmann, Consul General of Switzerland in Shanghai; ZhangHua Qian, Standing Committee Member of the Wuzhong District Committee, Deputy Secretary of the Economic Development Zone Party Work Committee, and Deputy Director of the Management Committee; Biosynth Board Member Nico Haller, Director at KKR and Biosynth CCO Philip Noone.

New biological technology facility opens in Suzhou, China

Nov 06 2024

Biosynth, a leading developer and supplier of essential raw materials and services for the diagnostics, vaccine, and pharmaceutical sectors, is pleased to announce the opening of its Biological Technology site at Lifebay, an innovative technology park in Suzhou, China. This new facility, featuring advanced laboratories, strengthens support for internal research initiatives and expands material supply for the domestic Life Science market.

The official opening on 29 October brought together local and national dignitaries, Life Science and pharmaceutical customers, and Biosynth’s partners. Representatives from Biosynth's Leadership Team, including Board Representative Nico Haller, Director at KKR, were also in attendance.

Dr Thomas Eisele, Chief Operations Officer at Biosynth, stated: “We’re excited to officially open the Biological Technology facility. This site exemplifies our commitment to innovation and excellence, serving as a vital production hub for internal materials and a key distribution centre for our clients across the region.”

Philip Noone, Chief Commercial Officer, added: “With the launch of our Lifebay facility in Suzhou, Biosynth can directly support IVD companies across China, offering a comprehensive portfolio of Biologics, Chemicals, and Complex Peptides. This new site enables us to provide unique diagnostic solutions targeting infectious diseases, oncology, and autoimmune conditions, specifically addressing emerging pathogens.”

Alessandra Vismara, General Manager for China, remarked: “Constructing and equipping this facility has been a significant endeavour. In the next phase, we will commission our biosafety level 2 laboratories, allowing us to broaden our offerings with additional biological diagnostic tools. Enzyme development and production tailored for local needs will complete the facility’s capabilities.”

More information online